Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma

  • Technology appraisal guidance
  • TA10
  • Published: 
Download guidance (PDF)

10 Sources of evidence

The following documentation and opinions were made available to the committee:

  • Assessment report: The effectiveness of inhaler devices for young children with asthma; Prepared by Payne N and Beard S, Trent Institute for Health Services Research, School of Health and Related Research, University of Sheffield; Wright, Brocklebank, D and Ram F, Bradford Hospitals NHS Trust; Taylor RS, National Institute for Clinical Excellence. March 2000.

Manufacturer or sponsor submissions:

  • AstraZeneca

  • Boehringer Ingelheim Ltd.

  • Aventis Pharma (formerly Rhône-Poulenc Rorer)

  • Boehringer Ingelheim Ltd.

  • Glaxo Wellcome

  • 3M Health Care Ltd.

  • Norton Healthcare

  • Yamanouchi Pharma Ltd

Professional or specialist group, patient or carer group and trade association submissions:

  • Association of British Health-Care Industries

  • British Medical Association

  • British Thoracic Society

  • National Asthma Campaign

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Physicians

The following experts were invited to make submissions to the Committee:

  • Dr Andrew Bush, Reader in paediatric respirology and honorary consultant paediatric chest physician, Royal Brompton Hospital, London.

  • Dr C O'Callaghan, Senior lecturer and consultant paediatrician, University of Leicester and Leicester Royal Infirmary Children's Hospital.

ISBN: 978-1-4731-5664-7